Pacira BioSciences Reiterated FY19 Exparel Sales $400M - $410M & Iovera Sales $8M - 10M

2019 Financial Guidance Pacira reiterated its full year 2019 financial guidance as follows: EXPAREL net product sales in the range of $400 million to $410 million.    iovera° net product sales in the

Benzinga · 11/07/2019 14:46

2019 Financial Guidance
Pacira reiterated its full year 2019 financial guidance as follows:

  • EXPAREL net product sales in the range of $400 million to $410 million.   
  • iovera° net product sales in the range of $8 million to $10 million.
  • Non-GAAP gross margins in the range of 75% to 76%.
  • Non-GAAP research and development (R&D) expense in the range of $60 million to $70 million.
  • Non-GAAP SG&A expense in the range of $180 million to $190 million.
  • Stock-based compensation in the range of $30 million to $35 million.